| Literature DB >> 32139868 |
Yueyue Zhou1, Lu Lin2, Heng Wang3, Zhichao Zhang3, Jizhong Zhou4, Nianzhi Jiao5,6.
Abstract
Ferulic acid is a ubiquitous phenolic compound in lignocellulose, which is recognized for its role in the microbialEntities:
Mesh:
Substances:
Year: 2020 PMID: 32139868 PMCID: PMC7058019 DOI: 10.1038/s42003-020-0824-5
Source DB: PubMed Journal: Commun Biol ISSN: 2399-3642
Plasmids and bacterial strains used in this study.
| Strain or plasmid | Relevant characteristics | Source or reference |
|---|---|---|
| Plasmids | ||
| pPROBE-GT | pVS1/p15a Gm gfp | [ |
| pBBR1MCS2 | pBBR1 oriV Kan | [ |
| pCas9 | pVS1/p15a Gm, Pmin:: | This study |
| pCas9n | pVS1/p15a Gm, Pmin:: | This study |
| pRed | pVS1/p15a Gm, PxylA:: λ-Red cassette, gfp | This study |
| pCas9-Red | pVS1/p15a Gm, PxylA:: λ-Red cassette, Pmin:: | This study |
| pCas9n1 | pVS1/p15a Gm, Ptrc:: gRNA( | This study |
| pCas9n-Red | pVS1/p15a Gm, PxylA:: λ-Red cassette, Pmin:: | This study |
| pgRNA | pVS1/p15a Gm, Ptrc:: gRNA( | This study |
| pDonor | pVS1/p15a Gm, 0.5 kb | This study |
| pgRNA-donor | pVS1/p15a Gm, Ptrc:: gRNA( | This study |
| pBgRNA | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-1 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-2 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-3 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-4 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-5 | pBBR1 oriV Kan, Ptrc:: gRNA(tesA), 0.5 kb | This study |
| pBBR1-6 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-7 | pBBR1 oriV Kan, Ptrc:: gRNA(tesB), 0.5 kb | This study |
| pBBR1-8 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-9 | pBBR1 oriV Kan, Ptrc:: gRNA(phaZ), 0.5 kb | This study |
| pBBR1-10 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-11 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-12 | pBBR1 oriV Kan, Ptrc:: gRNA(fcs), 0.5 kb | This study |
| pBBR1-13 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-14 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-15 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-16 | pBBR1 oriV Kan, Ptrc:: gRNA(vanAB), 0.5 kb | This study |
| pBBR1-17 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-18 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-19 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-20 | pBBR1 oriV Kan, Ptrc:: gRNA( | This study |
| pBBR1-2-1 | pBBR1 oriV Kan, Ptrc:: gRNA(pyrF), 0.5 kb pyrF donor up- pPROBE-GT vector sequence-0.5 kb pyrF donor down | This study |
| Strains | ||
| | Wild type | ATCC |
| KTG | KT2440 carrying pPROBE-GT | This study |
| KTΔ | KT2440 Δ | This study |
| KTc9n | KT2440 Δ | This study |
| KTc9nΔ | KTc9n Δ | This study |
| KTc9nΔ | KTc9n Δ | This study |
| KTc9nΔ | KTc9n ΔP | This study |
| KTpGT | KTc9n pPROBE-GT | This study |
| KTc9n1 | KTc9n P | This study |
| KTc9n2 | KTc9n1 P | This study |
| KTc9n3 | KTc9n Δ | This study |
| KTc9n4 | KTc9n P | This study |
| KTc9n5 | KTc9n P | This study |
| KTc9n6 | KTc9n P | This study |
| KTc9n7 | KTc9n Δ | This study |
| KTc9n8 | KTc9n Δ | This study |
| KTc9n9 | KTc9n Δ | This study |
| KTc9n10 | KTc9n Δ | This study |
| KTc9n11 | KTc9n Δ | This study |
| KTc9n12 | KTc9n Δ | This study |
| KTc9n13 | KTc9n Δ | This study |
| KTc9n14 | KTc9n PphaC1:: | This study |
| KTc9n15 | KTc9n Δ | This study |
| KTc9n16 | KTc9n Δ | This study |
| KTc9n17 | KTc9n6 Δ | This study |
| KTc9n18 | KTc9n6Δ | This study |
| KTc9n19 | KTc9n8Δ | This study |
| KTc9n20 | KTc9n8 Δ | This study |
Mutation efficiency of different genome-editing methods.
| Target gene | System | Plasmid | Copy number (copies per cell) | Component | Efficiency |
|---|---|---|---|---|---|
| Homologous recombination | pBBR1-1 | 60 | 0.5 kb donor template | 1/164990 | |
| λ-Red recombination | pRed | 13 | λ Red recombinase, | 1/42490 | |
| pBBR1-1 | 60 | donor template | |||
| CRISPR/Cas9 | pCas9 | 15 | Cas9, | 0 | |
| pBBR1-1 | 60 | gRNA, donor template | |||
| CRISPR/Cas9 and λ-Red recombinase | pCas9-Red | 8 | Cas9, λ Red recombinase, | 1/7730 | |
| pBBR1-1 | 60 | gRNA, donor template | |||
| CRISPR/Cas9n | pCas9n | 15 | Cas9n, | 1/7259 | |
| pBBR1-1 | 60 | gRNA, donor template | |||
| CRISPR/Cas9n and λ-Red recombinase | pCas9n-Red | 9 | Cas9n, λ Red recombinase, | 1/10 | |
| pBBR1-1 | 60 | gRNA, donor template |
Fig. 1Schematic of genome editing in P. putida KT2440 via the CRP strategy.
Strain KTc9n was constructed via introduction of the pBBR1-2 plasmid into P. putida KT2440. It integrated the Cas9n and λ-Red expression cassettes into the genome to replace pyrF. The procedure for icd deletion is shown as an example to illustrate the detailed strategy. Day 1: Electroporation of plasmid pBBR1-3 into KTc9n for icd knockout. Following electroporation, cells were grown on LB pressure medium (xylose+Ura++Km) at 30 °C, 200 rpm for 18 h for genome editing. Day 2: Transfer 1% of cultivated cells into 5 mL fresh 15 mM glucose-M9 minimal selective medium (Ura−), supplemented with 4 mM vanillic acid to induce pBBR1-3 plasmid curing. Colonies without green fluorescence indicated the icd gene was deleted and that plasmid pBBR1-3 was eliminated. Day 3: Introduce pBBR1-4 plasmid into KTc9nΔicd, to remove the pyrF marker. Day 4: Identify KTc9n9 mutant without pyrF selection marker from the LB selection plate (Ura++5-FOA).
Fig. 2Proposed ferulic acid-to-mcl-PHA bioconversion route.
a Metabolic pathways for ferulic acid-to-mcl-PHA bioconversion, including ferulic acid catabolism pathway, fatty acid biosynthesis pathway, β-oxidation pathway and PHA biosynthesis pathway. b Cell growth, NADH/NAD+ ratio, residual concentrations of ferulic acid in medium and mcl-PHA production by P. putida KT2440 and KTc9n. The two strains were grown on M9 mineral medium (65 mg L−1 NH4Cl) with 20 mM ferulic acid as the sole carbon substrate (n = 3 biologically independent experiments).
Fig. 3Metabolic engineering of P. putida KT2440 for enhanced ferulic acid degradation and tolerance.
a Organization of the ferulic acid catabolism locus in KT2440. P: promoter. IDs and gene names of the corresponding enzymes are shown. b Ferulic acid catabolism pathway. Dashed arrow indicates multiple steps. c–d Cell growth curves, NADH/NAD+ ratio, residual concentrations of ferulic acid and vanillic acid of the mutant strains. They were grown on M9 mineral medium (65 mg L−1 NH4Cl) with 20 mM ferulic acid as the sole carbon substrate (n = 3 biologically independent experiments). e, f Cell growth and residual concentrations of ferulic acid in medium of mutant strains. They were cultured in 40 mM ferulic acid-M9 mineral medium (65 mg L−1 NH4Cl) (n = 3 biologically independent experiments).
Fig. 4Metabolic engineering of P. putida KT2440 for enhanced mcl-PHA production.
a Schematic of mcl-PHA biosynthesis pathways that are involved in TCA cycle, fatty acid biosynthesis and β-oxidation. Genes that are knocked-out and knocked-in in KTc9n are marked. b Organization of the PHA biosynthetic genes of KT2440. IDs and gene names of the corresponding enzymes are shown. c, d The cell dry weight, PHA titer and cell growth of strains under 20 mM ferulic acid-65 mg L−1 NH4Cl condition (n = 3 biologically independent experiments).
Fig. 5Metabolic engineering of ferulic acid to mcl-PHA bioconversion in P. putida KT2440.
a Metabolic engineering of ferulic acid-to-mcl-PHA bioconversion in P. putida KT2440. Four modules were integrated to synthesize mcl-PHA from ferulic acid in KT2440. b, c The cell growth, residual ferulic acid in medium, and mcl-PHA titer of the engineered strains under 20 mM ferulic acid-65 mg L−1 NH4Cl condition (n = 3 biologically independent experiments). d, e The cell growth, residual ferulic acid in medium and mcl-PHA titer of the engineered strains under 20 mM ferulic acid-130 mg L−1 NH4Cl condition (n = 3 biologically independent experiments).
mcl-PHA production from aromatic compounds in Pseudomonas strains.
| Carbon Source (Ini-Con mM)a | Nitrogen Source (mg L−1) | Cultivation mode | CDW (mg L−1) | PHA titer (mg L−1) | Measurement method for PHA production | Organisms | References |
|---|---|---|---|---|---|---|---|
| Ferulic acid (20–15.74) | NH4Cl (130) | Shake flask batch | 540 | 59.3 | GC | This study | |
| Ferulic acid (20–19.06) | 780 | 268.3 | |||||
| Ferulic acid (20–15.74) | NH4Cl (65) | Shake flask batch | 540 | 65.4 | GC | ||
| 105.0 | Nile Red staining | ||||||
| 218.0 | Weighing | ||||||
| Ferulic acid (10–10) | NDb | Shake flask batch | 436 | 170.0 | Flow cytometry via Nile Red staining | [ | |
| 470 | 160.0 | ||||||
| Vanillic acid (15-ND) | NH4Cl (65) | Shake flask batch | 715 | 246 | Weighing | [ | |
| (NH4)2SO4 (130) | Fed-batch, flask | 483 | 241.0 | GC/MS | [ | ||
| (NH4)2SO4(528) | Fed-batch, flask, HCDc | 1758 | 953 | ||||
| Phenylacetic acid (15–15) | NaNH4PO4 4H2O (67) | Shake flask batch | 824 | 247.0 | Waters gel permeation chromatograph | [ | |
| Styrene (19-NDb) | 796 | 195.0 | |||||
| Styrene (20-ND) | NH4Cl (25) | Solid-state fermentation | 530 | 140.0 | GC | [ | |
| Benzene (20-ND) | 340 | 48.0 | |||||
| Benzene (11-ND) | NH4Cl (500) | Fed-batch fermentation | 290 | 2.9 | GC/MS | [ | |
| Toluene (20-ND) | NH4Cl (25) | Solid-state fermentation | 370 | 81.0 | GC | [ | |
| 720 | 160.0 | ||||||
| Toluene (9-ND) | NH4Cl (500) | Fed-batch fermentation | 290 | 16.2 | GC/MS | [ | |
| Ethylbenzene (20-ND) | NH4Cl (25) | Solid-state fermentation | 670 | 98.0 | GC | [ | |
| Ethylbenzene (8-ND) | NH4Cl (500) | Fed-batch fermentation | 260 | 8.8 | GC/MS | [ |
aIni-Con mM, initiate carbon substrate concentration - consumed carbon substrate concentration (mM).
bND, not determined.
cHCD, high-cell-density.
Comparison of different genetic editing tools in Pseudomonas.
| Method | Time (days) | Scarless | Markerless | Insertion | Efficiency | Efficient plasmid curing | Number of plasmid | Organisms | References |
|---|---|---|---|---|---|---|---|---|---|
| CRP | 4 | Yes | Yes | Yes | 100% | Cas9n-mediated plasmid curing | 2 | This study | |
| CRISPR/cas9-λ Red | 5 | Yes | Yes | Yes | 70–100% | Cas9-mediated plasmid curing | 2 | [ | |
| CRISPR/cas9-Ssr | 4–5 | Yes | Yes | limited | 13–93% | without antibiotic selection | 3 | [ | |
| I-SceI | 5–6 | Yes | Yes | ND | 14–81% | suicide vector/SacB | 2 | [ | |
| Flp-FRT | 5–6 | FRT site (48 bp) | Yes | ND | ND | without antibiotic selection | 2 | [ | |
| λ-Red-Cre/loxP | 4–6 | LoxP site (34 bp) | Yes | ND | 70–100% | suicide vector/ SacB | 1 plus Linear DNA | [ | |
| Homologous recombination with | 14 | GmR site | No | ND | ND | suicide vector | 1 | [ |
ND not determined.